INNOVIVA, INC. Net Cash Provided by (Used in) Continuing Operations
INNOVIVA, INC. (INVA) reported Net Cash Provided by (Used in) Continuing Operations of -$18.23 million for the 3-month period ending 2014-03-31, per its 10-Q filed 2014-05-07.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:NetCashProvidedByUsedInContinuingOperations · last filed 2014-05-07
- INNOVIVA, INC. net cash provided by (used in) continuing operations for the quarter ending 2014-03-31 was -$18.23M, a 110.65% decline year-over-year.
- INNOVIVA, INC. net cash provided by (used in) continuing operations for the quarter ending 2013-12-31 was -$28.38M.
- INNOVIVA, INC. net cash provided by (used in) continuing operations for the quarter ending 2013-09-30 was -$27.35M.
- INNOVIVA, INC. net cash provided by (used in) continuing operations for the quarter ending 2013-06-30 was -$66.83M, a 145.53% decline year-over-year.
- INNOVIVA, INC. net cash provided by (used in) continuing operations for fiscal 2013 was $48.66M, a 2.82% decline from fiscal 2012.
- INNOVIVA, INC. net cash provided by (used in) continuing operations for fiscal 2012 was $50.07M.
- INNOVIVA, INC. net cash provided by (used in) continuing operations for fiscal 2011 was -$118.56M, a 202.39% decline from fiscal 2010.
- INNOVIVA, INC. net cash provided by (used in) continuing operations for fiscal 2010 was $115.79M.
| Period end | Net Cash Provided by (Used in) Continuing Operations 3 month | Net Cash Provided by (Used in) Continuing Operations 6 month | Net Cash Provided by (Used in) Continuing Operations 9 month | Net Cash Provided by (Used in) Continuing Operations 12 month |
|---|---|---|---|---|
| 2014-03-31 | -$18.23M 10-Q · filed 2014-05-07 | -$46.62M derived: sum of 2 quarters · filed 2014-05-07 | -$73.97M derived: sum of 3 quarters · filed 2014-05-07 | -$140.79M derived: sum of 4 quarters · filed 2014-05-07 |
| 2013-12-31 | -$28.38M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | -$55.73M derived: sum of 2 quarters · filed 2014-03-03 | -$122.56M derived: sum of 3 quarters · filed 2014-03-03 | $48.66M 10-K · filed 2014-03-03 |
| 2013-09-30 | -$27.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-01 | -$94.18M derived: sum of 2 quarters · filed 2013-11-01 | $77.04M 10-Q · filed 2013-11-01 | $59.66M derived: sum of 4 quarters · filed 2014-05-07 |
| 2013-06-30 | -$66.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | $104.39M 10-Q · filed 2013-08-01 | $87.01M derived: sum of 3 quarters · filed 2014-05-07 | $38.15M derived: sum of 4 quarters · filed 2014-05-07 |
| 2013-03-31 | $171.22M 10-Q · filed 2014-05-07 | $153.84M derived: sum of 2 quarters · filed 2014-05-07 | $104.97M derived: sum of 3 quarters · filed 2014-05-07 | $251.76M derived: sum of 4 quarters · filed 2014-05-07 |
| 2012-12-31 | -$17.39M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | -$66.25M derived: sum of 2 quarters · filed 2014-03-03 | $80.54M derived: sum of 3 quarters · filed 2014-03-03 | $50.07M 10-K · filed 2014-03-03 |
| 2012-09-30 | -$48.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-01 | $97.92M derived: sum of 2 quarters · filed 2013-11-01 | $67.46M 10-Q · filed 2013-11-01 | $49.50M derived: sum of 4 quarters · filed 2014-03-03 |
| 2012-06-30 | $146.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | $116.32M 10-Q · filed 2013-08-01 | $98.36M derived: sum of 3 quarters · filed 2014-03-03 | $70.44M derived: sum of 4 quarters · filed 2014-03-03 |
| 2012-03-31 | -$30.47M 10-Q · filed 2013-05-01 | -$48.43M derived: sum of 2 quarters · filed 2014-03-03 | -$76.35M derived: sum of 3 quarters · filed 2014-03-03 | -$133.56M derived: sum of 4 quarters · filed 2014-03-03 |
| 2011-12-31 | -$17.96M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | -$45.88M derived: sum of 2 quarters · filed 2014-03-03 | -$103.10M derived: sum of 3 quarters · filed 2014-03-03 | -$118.56M 10-K · filed 2014-03-03 |
| 2011-09-30 | -$27.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-31 | -$85.14M derived: sum of 2 quarters · filed 2012-10-31 | -$100.60M 10-Q · filed 2012-10-31 | -$365.00K derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-06-30 | -$57.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-01 | -$72.67M 10-Q · filed 2012-08-01 | $27.56M derived: sum of 3 quarters · filed 2013-02-26 | |
| 2011-03-31 | -$15.46M 10-Q · filed 2012-05-02 | $84.77M derived: sum of 2 quarters · filed 2013-02-26 | ||
| 2010-12-31 | $100.23M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $115.79M 10-K · filed 2013-02-26 | ||
| 2010-09-30 | $15.56M 10-Q · filed 2011-11-02 | |||
| 2009-12-31 | -$44.74M 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |